Zilovertamab Biosimilar – Anti-ROR1 mAb – Research Grade

Description of Zilovertamab Biosimilar - Anti-ROR1 mAb - Research Grade

The Structure and

Activity of Zilovertamab Biosimilar – Anti-ROR1 mAb – Research Grade

Zilovertamab Biosimilar, also known as Anti-ROR1 mAb, is a monoclonal antibody that specifically targets the receptor tyrosine kinase-like orphan receptor 1 (ROR1). This therapeutic antibody is a biosimilar version of the original Zilovertamab, which has shown promising results in clinical trials for the treatment of various cancers.

The Structure of Zilovertamab Biosimilar

Zilovertamab Biosimilar is a fully humanized IgG1 monoclonal antibody, meaning that it is derived from human cells and has a structure similar to natural human antibodies. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL) and one variable domain (VL).

The variable domains of Zilovertamab Biosimilar are responsible for its specificity and binding to ROR1. They contain complementarity-determining regions (CDRs) that interact with the target receptor. The constant domains, on the other hand, play a role in the effector functions of the antibody, such as activating immune cells to attack cancer cells.

The Activity of Zilovertamab Biosimilar

Zilovertamab Biosimilar works by binding to ROR1, which is overexpressed in many types of cancer cells. ROR1 is a transmembrane protein that is involved in cell proliferation, survival, and migration. When Zilovertamab Biosimilar binds to ROR1, it blocks its signaling pathways, leading to inhibition of cancer cell growth and survival.

In addition to directly targeting

cancer cells, Zilovertamab Biosimilar also has effector functions that can activate the immune system to attack cancer cells. This is achieved through the antibody’s Fc region, which can bind to Fc receptors on immune cells and trigger immune responses, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

The Application of Zilovertamab Biosimilar

Zilovertamab Biosimilar is currently being investigated as a potential treatment for various types of cancer, including solid tumors and hematological malignancies. It has shown promising results in preclinical and early clinical studies, demonstrating its potential as a targeted therapy for cancer.

One of the main advantages of Zilovertamab Biosimilar is its specificity for ROR1, which is highly expressed in cancer cells but not in normal tissues. This minimizes the risk of off-target effects and reduces the potential for toxicity. In addition, its fully humanized structure reduces the risk of immune reactions, making it a safer option for patients.

In conclusion, Zilovertamab Biosimilar – Anti-ROR1 mAb – Research Grade is a promising therapeutic antibody that specifically targets ROR1 and has the potential to effectively treat various types of cancer. Its structure, activity, and application make it a valuable addition to the arsenal of cancer treatments, and further clinical trials will determine its efficacy and safety in treating cancer patients.

SDS-PAGE for Zilovertamab Biosimilar - Anti-ROR1 mAb

Zilovertamab Biosimilar - Anti-ROR1 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

Zilovertamab Biosimilar – Anti-ROR1 mAb – Research Grade binds to Human ROR1 recombinant protein in indirect ELISA Assay

Immobilized Human ROR1 recombinant protein (cat. No.PX-P6292) at 5µg/mL (100µL/well) can bind to Zilovertamab Biosimilar – Anti-ROR1 mAb – Research Grade (cat. No.PX-TA1743) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450